Post‐acute COVID‐19 syndrome (PCS) and health‐related quality of life (HRQoL)—A systematic review and meta‐analysis

  • Preeti Malik
    Department of Public Health Icahn school of Medicine at Mount Sinai New York New York USA
  • Karan Patel
    Department of Medicine Cooper Medical School of Rowan University Camden New Jersey USA
  • Candida Pinto
    Department of Public Health Icahn school of Medicine at Mount Sinai New York New York USA
  • Richa Jaiswal
    Department of Internal Medicine Medical University of South Carolina Charleston South Carolina USA
  • Raghavendra Tirupathi
    Department of Internal Medicine Keystone Health Chambersburg Pennsylvania USA
  • Shreejith Pillai
    Department of Internal Medicine Henry Ford Health System Detroit Michigan USA
  • Urvish Patel
    Department of Public Health Icahn school of Medicine at Mount Sinai New York New York USA

説明

<jats:title>Abstract</jats:title><jats:p>There is an established literature on the symptoms and complications of COVID‐19 but the after‐effects of COVID‐19 are not well understood with few studies reporting persistent symptoms and quality of life. We aim to evaluate the pooled prevalence of poor quality of life in post‐acute COVID‐19 syndrome (PCS) and conducted meta‐regression to evaluate the effects of persistent symptoms and intensive care unit (ICU) admission on the poor quality of life. We extracted data from observational studies describing persistent symptoms and quality of life in post‐COVID‐19 patients from March 10, 2020, to March 10, 2021, following PRISMA guidelines with a consensus of two independent reviewers. We calculated the pooled prevalence with 95% confidence interval (CI) and created forest plots using random‐effects models. A total of 12 studies with 4828 PCS patients were included. We found that amongst PCS patients, the pooled prevalence of poor quality of life (EQ‐VAS) was (59%; 95% CI: 42%–75%). Based on individual factors in the EQ‐5D‐5L questionnaire, the prevalence of mobility was (36, 10–67), personal care (8, 1–21), usual quality (28, 2–65), pain/discomfort (42, 28–55), and anxiety/depression (38, 19–58). The prevalence of persistent symptoms was fatigue (64, 54–73), dyspnea (39.5, 20–60), anosmia (20, 15–24), arthralgia (24.3, 14–36), headache (21, 3–47), sleep disturbances (47, 7–89), and mental health (14.5, 4–29). Meta‐regression analysis showed the poor quality of life was significantly higher among post‐COVID‐19 patients with ICU admission (<jats:italic>p</jats:italic> = 0.004) and fatigue (<jats:italic>p</jats:italic> = 0.0015). Our study concludes that PCS is associated with poor quality of life, persistent symptoms including fatigue, dyspnea, anosmia, sleep disturbances, and worse mental health. This suggests that we need more research on PCS patients to understand the risk factors causing it and eventually leading to poor quality of life.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ